 <h1>Ticlid Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>ticlopidine</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about ticlopidine. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Ticlid.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to ticlopidine: oral tablet</i></p><h3>Warning</h3><p class="blackboxWarning-title">Oral route (Tablet)</p><p>Ticlopidine can cause life-threatening hematological adverse reactions, including neutropenia/agranulocytosis, thrombotic thrombocytopenic purpura (TTP) and aplastic anemia. Hematological adverse reactions cannot be reliably predicted by any identified demographic or clinical characteristics. During the first 3 months of treatment, patients receiving ticlopidine must, therefore, be hematologically and clinically monitored for evidence of neutropenia or TTP. If any such evidence is seen, ticlopidine should be immediately discontinued.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, ticlopidine (the active ingredient contained in Ticlid) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking ticlopidine:</p><p>
<i>Less common or rare</i>
</p><ul>
<li>Abdominal or stomach pain (severe) or swelling</li>
<li>back pain</li>
<li>blistering, peeling, or loosening of the skin or lips or mucous membranes (moist lining of many body cavities, including the mouth, lips, inside of nose, anus, and vagina)</li>
<li>blood in eyes</li>
<li>bloody or black tarry stools</li>
<li>bruising or purple areas on skin</li>
<li>change in mental status</li>
<li>convulsions (seizures)</li>
<li>coughing up blood</li>
<li> dark or bloody urine</li>
<li>decreased alertness</li>
<li>dizziness</li>
<li>fever, chills, or sore throat </li>
<li>headache (severe or continuing)</li>
<li> joint pain or swelling</li>
<li>nosebleeds</li>
<li>pale color of skin</li>
<li>paralysis or problems with coordination</li>
<li>pinpoint red spots on skin</li>
<li>red lesions on the skin, often with a purple center</li>
<li>red, thickened, or scaly skin</li>
<li>sores, ulcers, or white spots in mouth</li>
<li>stammering or other difficulty in speaking</li>
<li>unusually heavy bleeding or oozing from cuts or wounds</li>
<li>unusual tiredness </li>
<li>unusually heavy or unexpected menstrual bleeding </li>
<li>vomiting of blood or material that looks like coffee grounds</li>
<li>weakness</li>
<li>yellow eyes or skin</li>
</ul><p>Check with your doctor as soon as possible if any of the following side effects occur while taking ticlopidine:</p><p>
<i>More common</i>
</p><ul>
<li>Skin rash</li>
</ul><p>
<i>Less common or rare</i>
</p><ul>
<li>General feeling of discomfort or illness</li>
<li> hives or itching of skin</li>
<li>ringing or buzzing in ears </li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of ticlopidine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach pain (mild)</li>
<li>diarrhea </li>
<li>indigestion</li>
<li>nausea</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Bloating or gas</li>
<li>dizziness</li>
<li>vomiting</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ticlopidine: oral tablet</i></p><h3>Hematologic</h3><p>The majority of cases of neutropenia, agranulocytosis, aplastic anemia, and thrombotic thrombocytopenic purpura occur during the first three months of treatment.  US physicians reported 100 cases of TTP between 1992 and 1997.  Delayed onset of neutropenia, after discontinuation of ticlopidine (the active ingredient contained in Ticlid)  has been reported.  Hematologic parameters should be monitored every other week for the first three months of therapy and ticlopidine should be discontinued if laboratory values are altered or if symptoms of infection or bleeding are noted.  Thereafter, the patient should be monitored for signs of infection.  Patients should be counseled concerning signs and symptoms of TTP (weakness, pallor, petechiae, purpura, dark urine, jaundice or mental status changes) and instructed to discontinue ticlopidine and immediately report any of these findings.  Platelet infusions may accelerate thrombosis and should be avoided if possible.</p>
<p></p>
<p>Ecchymosis, epistaxis, hematuria, conjunctival hemorrhage, and gastrointestinal bleeding have been associated with ticlopidine therapy.  Intracerebral bleeding occurred in approximately 0.5% of patients in clinical trials.</p>
<p></p>
<p>Postsurgical bleeding may also occur. To minimize the effects of postsurgical bleeding, it is generally recommended that ticlopidine be discontinued 2 weeks before any surgical or dental interventions.<sup>[Ref]</sup></p><p>Hematologic dyscrasias have been the most serious adverse effects associated with ticlopidine therapy.  Reversible neutropenia (severe in 0.9%) occurred in 2.4% of patients.  Thrombocytopenia, agranulocytosis, pancytopenia, hemolytic anemia with reticulocytosis, and aplastic anemia have been reported.   </p>
<p></p>
<p>Thrombotic thrombocytopenic purpura (TTP), not noted during clinical trials, has occurred at an estimated incidence of 1 case per 2000 to 4000 exposures.  Symptoms include thrombocytopenia, microangiopathic hemolytic anemia (fragmented RBCs on a peripheral smear), renal dysfunction, fever, and neurological changes.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Gastrointestinal disturbances have been noted in up to 40% of patients.  Dyspepsia, nausea, diarrhea, vomiting, flatulence, and gastric pain have occurred.  Some gastrointestinal symptoms lessen with continued therapy and administration with food may decrease gastrointestinal intolerance.  Cases of ticlopidine-induced chronic diarrhea have been reported.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Two case reports of patients developing maculopapular pruritic rashes following administration of clopidogrel have been reported.  The rash recurred in both patients after switching to ticlopidine (the active ingredient contained in Ticlid)   In one patient, rechallenge resulted in recurrence of the rash.  These two cases illustrate the possibility of cross-sensitivity between thienopyridines.<sup>[Ref]</sup></p><p>Dermatologic adverse effects have occurred frequently.  Rash, generally maculopapular or urticarial, has been experienced in up to 15% of treated patients.  At least one case of multiple fixed-drug eruptions, consisting of rash and generalized patches of hyperpigmentation, has been reported.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Cholestatic jaundice has developed within 1 to 4 months of initiating therapy.  Resolution of jaundice and normalization of hepatic enzymes concentrations occurred upon discontinuation of therapy.</p>
<p></p>
<p>Numerous cases of ticlopidine-induced cholestatic hepatitis have been reported.  Time to the onset of hepatotoxicity is variable and ranges from 1 week to 6 months after initiating ticlopidine (the active ingredient contained in Ticlid)  2 to 12 weeks in most patients.  In one patient, hepatotoxicity appeared 1 month after discontinuing ticlopidine because of rash.  Symptoms and liver abnormalities resolved following discontinuation of ticlopidine, typically within 1 to 3 months; however, recovery time may be protracted (i.e.  more than 12 months).  Cases of irreversible hepatic damage have not been reported.<sup>[Ref]</sup></p><p>Hepatic side effects typically have been mild and have included reversible elevations in liver function tests (up to 4%).  The incidence of cholestatic jaundice has increased.  Postmarketing side effects have included hepatitis and hepatic necrosis.<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Metabolic disturbances have included persistent elevation of total serum cholesterol.<sup>[Ref]</sup></p><h3>Renal</h3><p>Reversible renal failure has been reported in patients receiving ticlopidine (the active ingredient contained in Ticlid) after stent implantation.  Other postmarketing reports have included incidences of nephrotic syndrome.<sup>[Ref]</sup></p><h3>General</h3><p>Side effects have occurred in up to 50% of patients.  Generally, side effects have been mild and most frequently involved the gastrointestinal tract (30% to 40%).  Diarrhea, rash, nausea, vomiting, gastric pain, and neutropenia were the primary cause of a 21% discontinuation rate.  Asthenia and generalized pain have been reported.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Nervous system side effects of dizziness, anorexia, and headache have been reported.  Postmarketing reports of peripheral neuropathy have been noted.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Postmarketing hypersensitivity reactions have included allergic pneumonitis, angioedema, vasculitis, and serum sickness.  Several cases of ticlopidine-induced systemic and cutaneous lupus erythematosus (positive ANA) have been reported.  Clinical improvement occurred in all patients following withdrawal of ticlopidine (the active ingredient contained in Ticlid) <sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Postmarketing musculoskeletal side effects have included arthropathy and myositis.  At least one case of ticlopidine-associated arthritis has been reported.<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Saltiel E, Ward A "Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states." Drugs 34 (1987): 222-62</p><p id="ref_2">2. McTavish D, Faulds D, Goa KL "Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders [published erratum appears in Drugs 1990 Oct;40(4):following Table of Contents]." Drugs 40 (1990): 238-59</p><p id="ref_3">3. Quinn MW, Dillard TA "Delayed traumatic hemothorax on ticlopidine and aspirin for coronary stent." Chest 116 (1999): 257-60</p><p id="ref_4">4. Kupfer Y, Tessler S "Ticlopidine and thrombotic thrombocytopenia purpura." N Engl J Med 337 (1997): 1245</p><p id="ref_5">5. Mukamal KJ, Wu B "Ticlopidine-associated thrombotic thrombocytopenic purpura." Ann Intern Med 129 (1998): 837</p><p id="ref_6">6. Mallet L, Mallet J "Ticlopidine and fatal anemia in an elderly woman." Ann Pharmacother 28 (1994): 1169-71</p><p id="ref_7">7. Martinnunez G, Fdezsoria RR, Sanchezgil F, Benitezcano E "Aplastic anaemia and ticlopidine." Br J Haematol 85 (1993): 633</p><p id="ref_8">8. Steinhubl SR, Tan WA, Foody JM, Topol EJ "Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting." JAMA 281 (1999): 806-10</p><p id="ref_9">9. Haynes RB, Sandler RS, Larson EB, Pater JL, Yatsu FM "A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events." Arch Intern Med 152 (1992): 1376-80</p><p id="ref_10">10. Farver DK, Hansen LA "Delayed neutropenia with ticlopidine." Ann Pharmacother 28 (1994): 1344-6</p><p id="ref_11">11. Page Y, Tardy B, Zeni F, Comtet C, Terrana R, Bertrand JC "Thrombotic thrombocytopenic purpura related to ticlopidine." Lancet 337 (1991): 774-6</p><p id="ref_12">12. Hass WK, Easton JD, Adams HP, Jr  Pryse-Phillips W, Molony BA, Anderson S, Kamm B "A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group." N Engl J Med 321 (1989): 501-7</p><p id="ref_13">13. Arribalzaga K, Garciasuarez J, Lopezrubio M, Krsnik I, Calero MA, Delcampo JF "Sustained granulocyte recovery after g-CSF in a patient with ticlopidine-induced severe aplastic anemia." Am J Hematol 50 (1995): 313</p><p id="ref_14">14. Garnier G, Taillan B, Pesce A, Chichmanian RM, Dujardin P "Ticlopidine and severe aplastic anaemia." Br J Haematol 81 (1992): 459-60</p><p id="ref_15">15. Ellie E, Durrieu C, Besse P, Julien J, Gbipki-Benissan G "Thrombotic thrombocytopenic purpura associated with ticlopidine ." Stroke 23 (1992): 922-3</p><p id="ref_16">16. Bennett CL, Davidson CJ, Raisch DW, Weinberg PD, Bennett RH, Feldman MD "Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention." Arch Intern Med 159 (1999): 2524-8</p><p id="ref_17">17. Ferrer F, DeArriba F, Moraleda JM, Vicente V "Aplastic anaemia induced by ticlopidine after placement of coronary artery stents: Therapeutic role of granulocyte colony-stimulating factor." Clin Drug Invest 15 (1998): 261-2</p><p id="ref_18">18. Dunlop H "Serious hematologic reactions associated with ticlopidine - update." Can Med Assn J 161 (1999): 867-8</p><p id="ref_19">19. Dunn P "Aplastic anemia with ticlopidine therapy in two Chinese patients." Ann Pharmacother 30 (1996): 547</p><p id="ref_20">20. Weiner P, Paz R, Zidan F "Severe aplastic anemia due to ticlopidine." Isr J Med Sci 31 (1995): 444-5</p><p id="ref_21">21. Lesesve JF, Callat MP, Lenormand B, Monconduit M, Noblet C, Moore N, Caron F, Humbert G, Stamatoullas A, Tilly H "Hematological toxicity of ticlopidine." Am J Hematol 47 (1994): 149-50</p><p id="ref_22">22. Desager JP "Clinical pharmacokinetics of ticlopidine." Clin Pharmacokinet 26 (1994): 347-55</p><p id="ref_23">23. Carlson JA, Maesner JE "Fatal neutropenia and thrombocytopenia associated with ticlopidine." Ann Pharmacother 28 (1994): 1236-8</p><p id="ref_24">24. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D "Thrombotic thrombocytopenic purpura associated with ticlopidine." Ann Intern Med 128 (1998): 541-4</p><p id="ref_25">25. Bennett CL, Davidson CJ, Green D, Weinberg PD, Feldman MD "Ticlopidine and TTP coronary stenting." JAMA 282 (1999): 1717</p><p id="ref_26">26. Quinn MJ, Fitzgerald DJ "Ticlopidine and clopidogrel." Circulation 100 (1999): 1667-72</p><p id="ref_27">27. Troussard X, Mayo P, Mosquet B, Reman O, Leporrier M "Ticlopidine and severe aplastic anaemia ." Br J Haematol 82 (1992): 779-80</p><p id="ref_28">28. Rimbrot S, Kundzinsh E, Levy Y "Invasive aspergillosis in a patient with ticlopidine-induced agranulocytosis." Arch Intern Med 160 (2000): 3498-9</p><p id="ref_29">29. Ono K, Kurohara K, Yoshihara M, Shimamoto Y, Yamaguchi M "Agranulocytosis caused by ticlopidine and its mechanism." Am J Hematol 37 (1991): 239-42</p><p id="ref_30">30. Ochoa AB, Wolfe M, Lewis P, Lenihan DJ "Ticlopidine-induced neutropenia mimicking sepsis early after intracoronary stent placement." Clin Cardiol 21 (1998): 304-7</p><p id="ref_31">31. ParadisoHardy FL, Angelo CM, Lanctot KL, Cohen EA "Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality." Can Med Assn J 163 (2000): 1441-8</p><p id="ref_32">32. "Ticlopidine for prevention of stroke." Med Lett Drugs Ther 34 (1992): 65-6</p><p id="ref_33">33. Mataix R, Ojeda E, Perez MC, Jimenez S "Ticlopidine and severe aplastic anaemia." Br J Haematol 80 (1992): 125-6</p><p id="ref_34">34. Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, Lindgarde F, Persson G, Almgren B, Fagher B, Kjellstrom T, et al "Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study [published erratum appears in J Intern Med 1990 Dec;228(6):659]." J Intern Med 227 (1990): 301-8</p><p id="ref_35">35. Chen DK, Kim JS, Sutton DMC "Thrombotic thrombocytopenic purpura associated with ticlopidine use - A report of 3 cases and review of the literature." Arch Intern Med 159 (1999): 311-4</p><p id="ref_36">36. Ceylan C, Kirimli O, Akarsu M, Undar B, Guneri S "Early ticlopidine-induced hepatic dysfunction, dermatitis and irreversible aplastic anemia after coronary artery stenting." Am J Hematol 59 (1998): 260</p><p id="ref_37">37. Muszkat M, Shapira MY, Sviri S, Linton DM, Caraco Y "Ticlopidine-induced thrombotic thrombocytopenic purpura." Pharmacotherapy 18 (1998): 1352-5</p><p id="ref_38">38. "Product Information. Ticlid (ticlopidine)." Syntex Laboratories Inc, Palo Alto, CA. </p><p id="ref_39">39. Khelif A, Assouline D, Ffrench M, Chaumentin G, Viala JJ "Ticlopidine and aplastic anaemia." Br J Haematol 83 (1993): 678-9</p><p id="ref_40">40. Weisberg LA "The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study." Neurology 43 (1993): 27-31</p><p id="ref_41">41. Elangovan L "Thrombotic thrombocytopenic purpura associated with ticlopidine use." Arch Intern Med 159 (1999): 1624</p><p id="ref_42">42. Mansoor GA, Aziz K "Delayed chronic diarrhea and weight loss possibly due to ticlopidine therapy." Ann Pharmacother 31 (1997): 870-2</p><p id="ref_43">43. Bequemin JP "Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs." N Engl J Med 337 (1997): 1726-31</p><p id="ref_44">44. Berger PB, Bell MR, Hasdai D, Grill DE, Melby S, Holmes DR "Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement." Circulation 99 (1999): 248-53</p><p id="ref_45">45. Berrebi D, Sautet A, Flejou JF, Dauge MC, Peuchmaur M, Potet F "Ticlopidine induced colitis: a histopathological study including apoptosis." J Clin Pathol 51 (1998): 280-3</p><p id="ref_46">46. Fraga M, Garcia B, Agud JL, Marco J, de Juana P, Cervero M "Severe chronic diarrhea induced by ticlopidine." Ann Pharmacother 30 (1996): 1496</p><p id="ref_47">47. Borras-Blasco J,  Navarro-Ruiz A,  Gutierrez-Casbas A,  Matarredona-Catala J,  Gonzalez-Delgado M "Multiple fixed-drug eruption and diarrhea with ticlopidine." Ann Pharmacother 36 (2002): 344-5</p><p id="ref_48">48. Wall GC, Heyneman CA "Calcitonin in phantom limb pain." Ann Pharmacother 33 (1999): 499-501</p><p id="ref_49">49. Yosipovitch G, Rechavia E, Feinmesser M, David M "Adverse cutaneous reactions to ticlopidine in patients with coronary stents." J Am Acad Dermatol 41 (1999): 473-6</p><p id="ref_50">50. Makkar K,  Wilensky RL,  Julien MB,  Herrmann HC,  Spinler SA "Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents." Ann Pharmacother 40 (2006): 1204-7</p><p id="ref_51">51. Cannavo SP, Borgia F, Guarneri F, Vaccaro M "Acute generalized exanthematous pustulosis following use of ticlopidine." Br J Dermatol 142 (2000): 577-8</p><p id="ref_52">52. Hsi DH, Mock DT, Rocco TA "Toxic erythroderma due to ticlopidine." N Engl J Med 340 (1999): 1212</p><p id="ref_53">53. Ruiz-Valverde P, Zafon C, Segarra A, Ribera R, Piera L "Ticlopidine-induced granulomatous hepatitis." Ann Pharmacother 29 (1995): 633-4</p><p id="ref_54">54. Cassidy LJ, Schuster BG, Halparin LS "Probable ticlopidine-induced cholestatic hepatitis." Ann Pharmacother 29 (1995): 30-2</p><p id="ref_55">55. Yoder JD, Algozzine GJ, Hill GW "More ticlopidine-induced cholestatic jaundice." Am J Hosp Pharm 51 (1994): 1821-2</p><p id="ref_56">56. Iqbal M, Goenka P, Young MF, Thomas E, Borthwick TR "Ticlopidine-induced cholestatic hepatitis: Report of three cases and review of the literature." Dig Dis Sci 43 (1998): 2223-6</p><p id="ref_57">57. Colivicchi F, Magnanimi S, Sebastiani F, Silvestri R, Magnanimi R "Ticlopidine-induced chronic cholestatic hepatitis: a case report." Curr Ther Res Clin Exp 55 (1994): 929-31</p><p id="ref_58">58. Skurnik YD,  Tcherniak A,  Edlan K,  Sthoeger Z "Ticlopidine-induced cholestatic hepatitis." Ann Pharmacother 37 (2003): 371-5</p><p id="ref_59">59. Kubin CJ, Sherman O, Hussain KB, Feinman L "Delayed-onset ticlopidine-induced cholestatic jaundice." Pharmacotherapy 19 (1999): 1006-10</p><p id="ref_60">60. Greany JJ, Jr  Hess DA, Mahoney CD "Ticlopidine-induced cholestatic jaundice." Clin Pharm 12 (1993): 398-9</p><p id="ref_61">61. Klepser TB, Jogerst GJ "Ticlopidine-induced elevated liver enzymes." Pharmacotherapy 17 (1997): 819-21</p><p id="ref_62">62. Wengrower D "Possible ticlopidine-induced cholestatic jaundice." Am Fam Physician 62 (2000): 1258+</p><p id="ref_63">63. Goff JS "Lansoprazole: A cause of secretory diarrhea." Am J Gastroenterol 93 (1998): 2298-9</p><p id="ref_64">64. PerezBalsa AM, DeArce A, Castiella A, Lopez P, Ruibal M, RuizMartinez J, DeMunain AL, Masso JFM "Hepatotoxicity due to ticlopidine." Ann Pharmacother 32 (1998): 1250-1</p><p id="ref_65">65. Naschitz JE, Khamessi R, Elias N, Yeshurun D "Ticlopidine-induced prolonged cholestasis." J Toxicol Clin Toxicol 33 (1995): 379-80</p><p id="ref_66">66. Azar R, Boldron A, Bakhache E, Elazouzi A "Ticlopidine and renal function." Lancet 348 (1996): 1031</p><p id="ref_67">67. Zijlstra F, Elsman P "Ticlopidine and renal function - reply." Lancet 348 (1996): 1031</p><p id="ref_68">68. Virdee M, Collinson J, Stables RH "Ticlopidine and renal function." Lancet 348 (1996): 1031-2</p><p id="ref_69">69. Persoz CF, Cornella F, Kaeser P, Rochat T "Ticlopidine-induced interstitial pulmonary disease - A case report." Chest 119 (2001): 1963-5</p><p id="ref_70">70. Spiera RF,  Berman RS,  Werner AJ,  Spiera H "Ticlopidine-induced lupus: a report of 4 cases." Arch Intern Med 162 (2002): 2240-3</p><p id="ref_71">71. Persoz CF, Cornella F, Kaeser P, Rochat T "Ticlopidine-induced interstitial pulmonary disease - A case report." Chest 119 (2001): 1963-5</p><p id="ref_72">72. Reich A,  Bialynicki-Birula R,  Szepietowski JC "Drug-induced subacute cutaneous lupus erythematosus resulting from ticlopidine." Int J Dermatol 45 (2006): 1112-4</p><p id="ref_73">73. Dakik HA,  Salti I,  Haidar R,  Uthman IW "Ticlopidine associated with acute arthritis." BMJ 324 (2002): 27</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Ticlid (ticlopidine)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>En Español</li>
<li>Drug class: platelet aggregation inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ticlid &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Cerebral Thrombosis/Embolism</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to ticlopidine: oral tablet</i></p><h3>Hematologic</h3><p>The majority of cases of neutropenia, agranulocytosis, aplastic anemia, and thrombotic thrombocytopenic purpura occur during the first three months of treatment.  US physicians reported 100 cases of TTP between 1992 and 1997.  Delayed onset of neutropenia, after discontinuation of ticlopidine (the active ingredient contained in Ticlid)  has been reported.  Hematologic parameters should be monitored every other week for the first three months of therapy and ticlopidine should be discontinued if laboratory values are altered or if symptoms of infection or bleeding are noted.  Thereafter, the patient should be monitored for signs of infection.  Patients should be counseled concerning signs and symptoms of TTP (weakness, pallor, petechiae, purpura, dark urine, jaundice or mental status changes) and instructed to discontinue ticlopidine and immediately report any of these findings.  Platelet infusions may accelerate thrombosis and should be avoided if possible.</p><p></p><p>Ecchymosis, epistaxis, hematuria, conjunctival hemorrhage, and gastrointestinal bleeding have been associated with ticlopidine therapy.  Intracerebral bleeding occurred in approximately 0.5% of patients in clinical trials.</p><p></p><p>Postsurgical bleeding may also occur. To minimize the effects of postsurgical bleeding, it is generally recommended that ticlopidine be discontinued 2 weeks before any surgical or dental interventions.<sup>[Ref]</sup></p><p>Hematologic dyscrasias have been the most serious adverse effects associated with ticlopidine therapy.  Reversible neutropenia (severe in 0.9%) occurred in 2.4% of patients.  Thrombocytopenia, agranulocytosis, pancytopenia, hemolytic anemia with reticulocytosis, and aplastic anemia have been reported.   </p><p></p><p>Thrombotic thrombocytopenic purpura (TTP), not noted during clinical trials, has occurred at an estimated incidence of 1 case per 2000 to 4000 exposures.  Symptoms include thrombocytopenia, microangiopathic hemolytic anemia (fragmented RBCs on a peripheral smear), renal dysfunction, fever, and neurological changes.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>Gastrointestinal disturbances have been noted in up to 40% of patients.  Dyspepsia, nausea, diarrhea, vomiting, flatulence, and gastric pain have occurred.  Some gastrointestinal symptoms lessen with continued therapy and administration with food may decrease gastrointestinal intolerance.  Cases of ticlopidine-induced chronic diarrhea have been reported.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>Two case reports of patients developing maculopapular pruritic rashes following administration of clopidogrel have been reported.  The rash recurred in both patients after switching to ticlopidine (the active ingredient contained in Ticlid)   In one patient, rechallenge resulted in recurrence of the rash.  These two cases illustrate the possibility of cross-sensitivity between thienopyridines.<sup>[Ref]</sup></p><p>Dermatologic adverse effects have occurred frequently.  Rash, generally maculopapular or urticarial, has been experienced in up to 15% of treated patients.  At least one case of multiple fixed-drug eruptions, consisting of rash and generalized patches of hyperpigmentation, has been reported.<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Cholestatic jaundice has developed within 1 to 4 months of initiating therapy.  Resolution of jaundice and normalization of hepatic enzymes concentrations occurred upon discontinuation of therapy.</p><p></p><p>Numerous cases of ticlopidine-induced cholestatic hepatitis have been reported.  Time to the onset of hepatotoxicity is variable and ranges from 1 week to 6 months after initiating ticlopidine (the active ingredient contained in Ticlid)  2 to 12 weeks in most patients.  In one patient, hepatotoxicity appeared 1 month after discontinuing ticlopidine because of rash.  Symptoms and liver abnormalities resolved following discontinuation of ticlopidine, typically within 1 to 3 months; however, recovery time may be protracted (i.e.  more than 12 months).  Cases of irreversible hepatic damage have not been reported.<sup>[Ref]</sup></p><p>Hepatic side effects typically have been mild and have included reversible elevations in liver function tests (up to 4%).  The incidence of cholestatic jaundice has increased.  Postmarketing side effects have included hepatitis and hepatic necrosis.<sup>[Ref]</sup></p><h3>Metabolic</h3><p>Metabolic disturbances have included persistent elevation of total serum cholesterol.<sup>[Ref]</sup></p><h3>Renal</h3><p>Reversible renal failure has been reported in patients receiving ticlopidine (the active ingredient contained in Ticlid) after stent implantation.  Other postmarketing reports have included incidences of nephrotic syndrome.<sup>[Ref]</sup></p><h3>General</h3><p>Side effects have occurred in up to 50% of patients.  Generally, side effects have been mild and most frequently involved the gastrointestinal tract (30% to 40%).  Diarrhea, rash, nausea, vomiting, gastric pain, and neutropenia were the primary cause of a 21% discontinuation rate.  Asthenia and generalized pain have been reported.<sup>[Ref]</sup></p><h3>Nervous system</h3><p>Nervous system side effects of dizziness, anorexia, and headache have been reported.  Postmarketing reports of peripheral neuropathy have been noted.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p>Postmarketing hypersensitivity reactions have included allergic pneumonitis, angioedema, vasculitis, and serum sickness.  Several cases of ticlopidine-induced systemic and cutaneous lupus erythematosus (positive ANA) have been reported.  Clinical improvement occurred in all patients following withdrawal of ticlopidine (the active ingredient contained in Ticlid) <sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p>Postmarketing musculoskeletal side effects have included arthropathy and myositis.  At least one case of ticlopidine-associated arthritis has been reported.<sup>[Ref]</sup></p><p id="ref_1">1. Saltiel E, Ward A "Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states." Drugs 34 (1987): 222-62</p><p id="ref_2">2. McTavish D, Faulds D, Goa KL "Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders [published erratum appears in Drugs 1990 Oct;40(4):following Table of Contents]." Drugs 40 (1990): 238-59</p><p id="ref_3">3. Quinn MW, Dillard TA "Delayed traumatic hemothorax on ticlopidine and aspirin for coronary stent." Chest 116 (1999): 257-60</p><p id="ref_4">4. Kupfer Y, Tessler S "Ticlopidine and thrombotic thrombocytopenia purpura." N Engl J Med 337 (1997): 1245</p><p id="ref_5">5. Mukamal KJ, Wu B "Ticlopidine-associated thrombotic thrombocytopenic purpura." Ann Intern Med 129 (1998): 837</p><p id="ref_6">6. Mallet L, Mallet J "Ticlopidine and fatal anemia in an elderly woman." Ann Pharmacother 28 (1994): 1169-71</p><p id="ref_7">7. Martinnunez G, Fdezsoria RR, Sanchezgil F, Benitezcano E "Aplastic anaemia and ticlopidine." Br J Haematol 85 (1993): 633</p><p id="ref_8">8. Steinhubl SR, Tan WA, Foody JM, Topol EJ "Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting." JAMA 281 (1999): 806-10</p><p id="ref_9">9. Haynes RB, Sandler RS, Larson EB, Pater JL, Yatsu FM "A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events." Arch Intern Med 152 (1992): 1376-80</p><p id="ref_10">10. Farver DK, Hansen LA "Delayed neutropenia with ticlopidine." Ann Pharmacother 28 (1994): 1344-6</p><p id="ref_11">11. Page Y, Tardy B, Zeni F, Comtet C, Terrana R, Bertrand JC "Thrombotic thrombocytopenic purpura related to ticlopidine." Lancet 337 (1991): 774-6</p><p id="ref_12">12. Hass WK, Easton JD, Adams HP, Jr  Pryse-Phillips W, Molony BA, Anderson S, Kamm B "A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group." N Engl J Med 321 (1989): 501-7</p><p id="ref_13">13. Arribalzaga K, Garciasuarez J, Lopezrubio M, Krsnik I, Calero MA, Delcampo JF "Sustained granulocyte recovery after g-CSF in a patient with ticlopidine-induced severe aplastic anemia." Am J Hematol 50 (1995): 313</p><p id="ref_14">14. Garnier G, Taillan B, Pesce A, Chichmanian RM, Dujardin P "Ticlopidine and severe aplastic anaemia." Br J Haematol 81 (1992): 459-60</p><p id="ref_15">15. Ellie E, Durrieu C, Besse P, Julien J, Gbipki-Benissan G "Thrombotic thrombocytopenic purpura associated with ticlopidine ." Stroke 23 (1992): 922-3</p><p id="ref_16">16. Bennett CL, Davidson CJ, Raisch DW, Weinberg PD, Bennett RH, Feldman MD "Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention." Arch Intern Med 159 (1999): 2524-8</p><p id="ref_17">17. Ferrer F, DeArriba F, Moraleda JM, Vicente V "Aplastic anaemia induced by ticlopidine after placement of coronary artery stents: Therapeutic role of granulocyte colony-stimulating factor." Clin Drug Invest 15 (1998): 261-2</p><p id="ref_18">18. Dunlop H "Serious hematologic reactions associated with ticlopidine - update." Can Med Assn J 161 (1999): 867-8</p><p id="ref_19">19. Dunn P "Aplastic anemia with ticlopidine therapy in two Chinese patients." Ann Pharmacother 30 (1996): 547</p><p id="ref_20">20. Weiner P, Paz R, Zidan F "Severe aplastic anemia due to ticlopidine." Isr J Med Sci 31 (1995): 444-5</p><p id="ref_21">21. Lesesve JF, Callat MP, Lenormand B, Monconduit M, Noblet C, Moore N, Caron F, Humbert G, Stamatoullas A, Tilly H "Hematological toxicity of ticlopidine." Am J Hematol 47 (1994): 149-50</p><p id="ref_22">22. Desager JP "Clinical pharmacokinetics of ticlopidine." Clin Pharmacokinet 26 (1994): 347-55</p><p id="ref_23">23. Carlson JA, Maesner JE "Fatal neutropenia and thrombocytopenia associated with ticlopidine." Ann Pharmacother 28 (1994): 1236-8</p><p id="ref_24">24. Bennett CL, Weinberg PD, Rozenberg-Ben-Dror K, Yarnold PR, Kwaan HC, Green D "Thrombotic thrombocytopenic purpura associated with ticlopidine." Ann Intern Med 128 (1998): 541-4</p><p id="ref_25">25. Bennett CL, Davidson CJ, Green D, Weinberg PD, Feldman MD "Ticlopidine and TTP coronary stenting." JAMA 282 (1999): 1717</p><p id="ref_26">26. Quinn MJ, Fitzgerald DJ "Ticlopidine and clopidogrel." Circulation 100 (1999): 1667-72</p><p id="ref_27">27. Troussard X, Mayo P, Mosquet B, Reman O, Leporrier M "Ticlopidine and severe aplastic anaemia ." Br J Haematol 82 (1992): 779-80</p><p id="ref_28">28. Rimbrot S, Kundzinsh E, Levy Y "Invasive aspergillosis in a patient with ticlopidine-induced agranulocytosis." Arch Intern Med 160 (2000): 3498-9</p><p id="ref_29">29. Ono K, Kurohara K, Yoshihara M, Shimamoto Y, Yamaguchi M "Agranulocytosis caused by ticlopidine and its mechanism." Am J Hematol 37 (1991): 239-42</p><p id="ref_30">30. Ochoa AB, Wolfe M, Lewis P, Lenihan DJ "Ticlopidine-induced neutropenia mimicking sepsis early after intracoronary stent placement." Clin Cardiol 21 (1998): 304-7</p><p id="ref_31">31. ParadisoHardy FL, Angelo CM, Lanctot KL, Cohen EA "Hematologic dyscrasia associated with ticlopidine therapy: evidence for causality." Can Med Assn J 163 (2000): 1441-8</p><p id="ref_32">32. "Ticlopidine for prevention of stroke." Med Lett Drugs Ther 34 (1992): 65-6</p><p id="ref_33">33. Mataix R, Ojeda E, Perez MC, Jimenez S "Ticlopidine and severe aplastic anaemia." Br J Haematol 80 (1992): 125-6</p><p id="ref_34">34. Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, Lindgarde F, Persson G, Almgren B, Fagher B, Kjellstrom T, et al "Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study [published erratum appears in J Intern Med 1990 Dec;228(6):659]." J Intern Med 227 (1990): 301-8</p><p id="ref_35">35. Chen DK, Kim JS, Sutton DMC "Thrombotic thrombocytopenic purpura associated with ticlopidine use - A report of 3 cases and review of the literature." Arch Intern Med 159 (1999): 311-4</p><p id="ref_36">36. Ceylan C, Kirimli O, Akarsu M, Undar B, Guneri S "Early ticlopidine-induced hepatic dysfunction, dermatitis and irreversible aplastic anemia after coronary artery stenting." Am J Hematol 59 (1998): 260</p><p id="ref_37">37. Muszkat M, Shapira MY, Sviri S, Linton DM, Caraco Y "Ticlopidine-induced thrombotic thrombocytopenic purpura." Pharmacotherapy 18 (1998): 1352-5</p><p id="ref_38">38. "Product Information. Ticlid (ticlopidine)." Syntex Laboratories Inc, Palo Alto, CA. </p><p id="ref_39">39. Khelif A, Assouline D, Ffrench M, Chaumentin G, Viala JJ "Ticlopidine and aplastic anaemia." Br J Haematol 83 (1993): 678-9</p><p id="ref_40">40. Weisberg LA "The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study." Neurology 43 (1993): 27-31</p><p id="ref_41">41. Elangovan L "Thrombotic thrombocytopenic purpura associated with ticlopidine use." Arch Intern Med 159 (1999): 1624</p><p id="ref_42">42. Mansoor GA, Aziz K "Delayed chronic diarrhea and weight loss possibly due to ticlopidine therapy." Ann Pharmacother 31 (1997): 870-2</p><p id="ref_43">43. Bequemin JP "Effect of ticlopidine on the long-term patency of saphenous-vein bypass grafts in the legs." N Engl J Med 337 (1997): 1726-31</p><p id="ref_44">44. Berger PB, Bell MR, Hasdai D, Grill DE, Melby S, Holmes DR "Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement." Circulation 99 (1999): 248-53</p><p id="ref_45">45. Berrebi D, Sautet A, Flejou JF, Dauge MC, Peuchmaur M, Potet F "Ticlopidine induced colitis: a histopathological study including apoptosis." J Clin Pathol 51 (1998): 280-3</p><p id="ref_46">46. Fraga M, Garcia B, Agud JL, Marco J, de Juana P, Cervero M "Severe chronic diarrhea induced by ticlopidine." Ann Pharmacother 30 (1996): 1496</p><p id="ref_47">47. Borras-Blasco J,  Navarro-Ruiz A,  Gutierrez-Casbas A,  Matarredona-Catala J,  Gonzalez-Delgado M "Multiple fixed-drug eruption and diarrhea with ticlopidine." Ann Pharmacother 36 (2002): 344-5</p><p id="ref_48">48. Wall GC, Heyneman CA "Calcitonin in phantom limb pain." Ann Pharmacother 33 (1999): 499-501</p><p id="ref_49">49. Yosipovitch G, Rechavia E, Feinmesser M, David M "Adverse cutaneous reactions to ticlopidine in patients with coronary stents." J Am Acad Dermatol 41 (1999): 473-6</p><p id="ref_50">50. Makkar K,  Wilensky RL,  Julien MB,  Herrmann HC,  Spinler SA "Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents." Ann Pharmacother 40 (2006): 1204-7</p><p id="ref_51">51. Cannavo SP, Borgia F, Guarneri F, Vaccaro M "Acute generalized exanthematous pustulosis following use of ticlopidine." Br J Dermatol 142 (2000): 577-8</p><p id="ref_52">52. Hsi DH, Mock DT, Rocco TA "Toxic erythroderma due to ticlopidine." N Engl J Med 340 (1999): 1212</p><p id="ref_53">53. Ruiz-Valverde P, Zafon C, Segarra A, Ribera R, Piera L "Ticlopidine-induced granulomatous hepatitis." Ann Pharmacother 29 (1995): 633-4</p><p id="ref_54">54. Cassidy LJ, Schuster BG, Halparin LS "Probable ticlopidine-induced cholestatic hepatitis." Ann Pharmacother 29 (1995): 30-2</p><p id="ref_55">55. Yoder JD, Algozzine GJ, Hill GW "More ticlopidine-induced cholestatic jaundice." Am J Hosp Pharm 51 (1994): 1821-2</p><p id="ref_56">56. Iqbal M, Goenka P, Young MF, Thomas E, Borthwick TR "Ticlopidine-induced cholestatic hepatitis: Report of three cases and review of the literature." Dig Dis Sci 43 (1998): 2223-6</p><p id="ref_57">57. Colivicchi F, Magnanimi S, Sebastiani F, Silvestri R, Magnanimi R "Ticlopidine-induced chronic cholestatic hepatitis: a case report." Curr Ther Res Clin Exp 55 (1994): 929-31</p><p id="ref_58">58. Skurnik YD,  Tcherniak A,  Edlan K,  Sthoeger Z "Ticlopidine-induced cholestatic hepatitis." Ann Pharmacother 37 (2003): 371-5</p><p id="ref_59">59. Kubin CJ, Sherman O, Hussain KB, Feinman L "Delayed-onset ticlopidine-induced cholestatic jaundice." Pharmacotherapy 19 (1999): 1006-10</p><p id="ref_60">60. Greany JJ, Jr  Hess DA, Mahoney CD "Ticlopidine-induced cholestatic jaundice." Clin Pharm 12 (1993): 398-9</p><p id="ref_61">61. Klepser TB, Jogerst GJ "Ticlopidine-induced elevated liver enzymes." Pharmacotherapy 17 (1997): 819-21</p><p id="ref_62">62. Wengrower D "Possible ticlopidine-induced cholestatic jaundice." Am Fam Physician 62 (2000): 1258+</p><p id="ref_63">63. Goff JS "Lansoprazole: A cause of secretory diarrhea." Am J Gastroenterol 93 (1998): 2298-9</p><p id="ref_64">64. PerezBalsa AM, DeArce A, Castiella A, Lopez P, Ruibal M, RuizMartinez J, DeMunain AL, Masso JFM "Hepatotoxicity due to ticlopidine." Ann Pharmacother 32 (1998): 1250-1</p><p id="ref_65">65. Naschitz JE, Khamessi R, Elias N, Yeshurun D "Ticlopidine-induced prolonged cholestasis." J Toxicol Clin Toxicol 33 (1995): 379-80</p><p id="ref_66">66. Azar R, Boldron A, Bakhache E, Elazouzi A "Ticlopidine and renal function." Lancet 348 (1996): 1031</p><p id="ref_67">67. Zijlstra F, Elsman P "Ticlopidine and renal function - reply." Lancet 348 (1996): 1031</p><p id="ref_68">68. Virdee M, Collinson J, Stables RH "Ticlopidine and renal function." Lancet 348 (1996): 1031-2</p><p id="ref_69">69. Persoz CF, Cornella F, Kaeser P, Rochat T "Ticlopidine-induced interstitial pulmonary disease - A case report." Chest 119 (2001): 1963-5</p><p id="ref_70">70. Spiera RF,  Berman RS,  Werner AJ,  Spiera H "Ticlopidine-induced lupus: a report of 4 cases." Arch Intern Med 162 (2002): 2240-3</p><p id="ref_71">71. Persoz CF, Cornella F, Kaeser P, Rochat T "Ticlopidine-induced interstitial pulmonary disease - A case report." Chest 119 (2001): 1963-5</p><p id="ref_72">72. Reich A,  Bialynicki-Birula R,  Szepietowski JC "Drug-induced subacute cutaneous lupus erythematosus resulting from ticlopidine." Int J Dermatol 45 (2006): 1112-4</p><p id="ref_73">73. Dakik HA,  Salti I,  Haidar R,  Uthman IW "Ticlopidine associated with acute arthritis." BMJ 324 (2002): 27</p><h2>More about Ticlid (ticlopidine)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Compare Alternatives</li>
<li>En Español</li>
<li>Drug class: platelet aggregation inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Ticlid &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Cerebral Thrombosis/Embolism</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>